论文部分内容阅读
目的采用循证医学的方法评价甘露聚糖肽联合顺铂对比单用顺铂治疗恶性胸腔积液的有效性和安全性。方法计算机检索中国生物医学文献数据库、中国期刊全文数据库、中文科技期刊全文数据库、万方数据库,收集甘露聚糖肽联合顺铂对比单用顺铂治疗恶性胸腔积液的随机对照试验,检索时间为各数据库建库至2011年3月。对文献进行质量评价,用RevMan 5.0软件对数据进行Meta分析。结果共纳入6项研究,所有文献质量均为C级。共收入388例患者,Meta分析结果显示甘露聚糖肽联合顺铂组与单用顺铂组相比,总有效率前者高于后者,差异有统计学意义(P<0.05);消化道不良反应发生率两组组间差异无统计学意义(P=0.05);骨髓抑制发生率前者低于后者,差异有统计学意义(P<0.05);Karnofsky评分提高率前者高于后者,差异有统计学意义(P<0.05)。结论系统评价表明,甘露聚糖肽联合顺铂治疗恶性胸腔积液的疗效优于单用顺铂的方案。
Objective To evaluate the efficacy and safety of mannan-polysaccharide combined with cisplatin versus cisplatin in the treatment of malignant pleural effusion by evidence-based medicine. Methods A computer-controlled randomized controlled clinical trial was conducted to compare the efficacy and safety of mannan-polysaccharide combined with cisplatin in the treatment of malignant pleural effusion in China. The retrieval time was Each database database to March 2011. The quality of the literature was evaluated and RevMan 5.0 software was used to perform meta-analysis of the data. Results A total of six studies were included, all of which were of grade C quality. A total of 388 patients were enrolled in this study. The results of Meta analysis showed that the total effective rate was higher in the mannan and cisplatin groups than in the cisplatin alone group (P <0.05) There was no significant difference in the incidence of the reaction between the two groups (P = 0.05); the incidence of bone marrow suppression was lower in the former than the latter (P <0.05); the Karnofsky score was higher in the former than the latter There was statistical significance (P <0.05). Conclusions The systematic reviews show that the efficacy of mannan plus cisplatin in the treatment of malignant pleural effusion is superior to that of cisplatin alone.